<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01830361</url>
  </required_header>
  <id_info>
    <org_study_id>TUD-MIDOKI-052</org_study_id>
    <secondary_id>2011-002567-17</secondary_id>
    <nct_id>NCT01830361</nct_id>
  </id_info>
  <brief_title>Trial to Assess the Efficacy of Midostaurin (PKC412) in Patients With c-KIT or FLT3-ITD Mutated t(8;21) AML</brief_title>
  <acronym>MIDOKIT</acronym>
  <official_title>A Single-arm Phase II Trial to Assess the Efficacy of Midostaurin (PKC412) Added to Standard Primary Therapy in Patients With Newly Diagnosed c-KIT or FLT3-ITD Mutated t(8;21) AML</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Technische Universität Dresden</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the efficacy of tyrosine-kinase inhibitor midostaurin in c-KIT or FLT3-ITD mutated&#xD;
      t(8;21) AML. To assess the efficacy of midostaurin depending on the type of c-KIT mutation&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AML patients displaying t(8;21) have a relatively favourable outcome. Nevertheless, only&#xD;
      approximately 50% of patients carrying this cytogenetic aberration are alive at 5 years. This&#xD;
      suggests that some patients have more aggressive leukemic phenotypes and indicates the need&#xD;
      for treatment optimization with novel therapies.&#xD;
&#xD;
      The mutated KIT gene as well as the FLT3-ITD mutation have recently been identified as&#xD;
      factors most likely to explain the heterogeneous clinical outcomes within the group of&#xD;
      t(8;21) AML. The FLT3 and c-KIT genes encode type III receptor tyrosine kinases (RTK) with&#xD;
      important and partly redundant functions in early hematopoietic stem cells. Various&#xD;
      activating mutations have been described for both genes. For c-KIT, the incidence ranges from&#xD;
      17 to 48% depending on the source population and type of mutations determined. It has been&#xD;
      consistently shown that in AMLs with t(8;21), mutated c-KIT is associated with a dramatically&#xD;
      increased risk of relapse and reduced overall survival compared to their unmutated&#xD;
      counterparts. The FLT3-ITD mutation has a similar negative effect on prognosis in the patient&#xD;
      group of t(8;21) mutated AMLs as c-KIT.&#xD;
&#xD;
      PKC412 (midostaurin) is known to inhibit the c-KIT RTK activity as well as the FLT3 kinase,&#xD;
      both in patients with ITD and TKD mutations. It should therefore be possible to abrogate the&#xD;
      negative impact of pathologically increased c-KIT or FLT3-ITD activity on relapse and overall&#xD;
      survival by using midostaurin in this patient population. Aim of the proposed clinical trial&#xD;
      is to prove the efficacy of midostaurin in c-KIT or FLT3-ITD mutated t(8;21)- AMLs in an&#xD;
      open-label one-arm design.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 13, 2013</start_date>
  <completion_date type="Actual">October 30, 2019</completion_date>
  <primary_completion_date type="Actual">October 30, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free Survival</measure>
    <time_frame>2-year Event-free Survival</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to relapse</measure>
    <time_frame>2-years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2-years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival</measure>
    <time_frame>2-years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>morphologic and molecular CR rate</measure>
    <time_frame>2-years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of AEs/SAEs</measure>
    <time_frame>until 30 days after end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRD kinetics (molecular residual disease)</measure>
    <time_frame>2-years</time_frame>
    <description>molecular diagnostics of markers in peripheral blood / bone marrow</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of relapse</measure>
    <time_frame>2-year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>midostaurin (PKC412), capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>midostaurin 50 mg (two 25 mg capsules) is given in combination with the second of two induction cycles and in combination with three cycles of high-dose cytarabine (HiDAC) consolidation chemotherapies and maintenance treatment in patients with c-kit or FLT3-ITD positive t(8;21) AML in an open-label one-arm design. The first cycle of induction is not part of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>midostaurin (PKC412)</intervention_name>
    <description>Midostaurin 50 mg (2 capsules) twice daily days 8-21 in induction II + consolidation I-III; maintenance treatment twice daily continuously for 12 months</description>
    <arm_group_label>midostaurin (PKC412), capsules</arm_group_label>
    <other_name>Rydapt</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of c-KIT mutated t(8;21) AML i.e.&#xD;
&#xD;
               1. &gt;20% myeloid blasts in bone marrow and/or peripheral blood at initial diagnosis&#xD;
&#xD;
               2. Plus cytogenetic diagnosis of aberration t(8;21)/AML1-ETO&#xD;
&#xD;
               3. Plus mutation of c-KIT gene (mut-KIT17 or mut-KIT8) or FLT3-ITD mutation or both&#xD;
                  c-KIT and FLT3-ITD mutations&#xD;
&#xD;
          -  Chemoresponsive disease as determined by early bone marrow assessment on day 14-16&#xD;
             after first cycle of induction therapy with cytarabine in combination with&#xD;
             daunorubicine or idarubicine, or mitoxantrone- Fit for further intensive chemotherapy&#xD;
&#xD;
          -  Age 18-65 years&#xD;
&#xD;
          -  ECOG performance status of 0-2&#xD;
&#xD;
          -  Life expectancy of at least 12 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Primary refractory or previously relapsed AML&#xD;
&#xD;
          -  Non-eligibility for high-dose cytarabine based consolidation, e.g. intolerance to&#xD;
             cytarabine&#xD;
&#xD;
          -  Inability to swallow oral medications&#xD;
&#xD;
          -  Symptomatic congestive heart failure&#xD;
&#xD;
          -  Bilirubin &gt;2.5 x upper limit of normal&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph Röllig, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medizinische Fakultät der TU Dresden, Medizinische Klinik und Poliklinik I</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinikum Chemnitz gGmbH, Klinik für Innere Medizin III</name>
      <address>
        <city>Chemnitz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Dresden Medizinische Klinik und Poliklinik I</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen, Medizinische Klinik 5</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johann-Wolfgang-Goethe Universität</name>
      <address>
        <city>Frankfurt Main</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena, Klinik für Innere Medizin II</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Gießen und Marburg GmbH</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Nord</name>
      <address>
        <city>Nürnberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität Regensburg</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.sal-aml.org</url>
    <description>Website Study Alliance Leukemia (coordinating study group)</description>
  </link>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>March 25, 2013</study_first_submitted>
  <study_first_submitted_qc>April 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2013</study_first_posted>
  <last_update_submitted>August 5, 2020</last_update_submitted>
  <last_update_submitted_qc>August 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>c-KIT</keyword>
  <keyword>FLT3-ITD</keyword>
  <keyword>t(8;21)</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>midostaurin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midostaurin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

